thyroxine has been researched along with Abdominal Epilepsy in 6 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lacosamide is a newer-generation AED, not known to induce or strongly inhibit cytochrome P450 (CYP450) enzymes." | 2.82 | Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial. ( Brandt, C; De Backer, M; Dedeken, P; Eckhardt, K; Elger, CE; Elmoufti, S; Rademacher, M; Tennigkeit, F, 2016) |
| "Hashimoto encephalopathy is a chronic relapsing steroid responsive encephalopathy characterized by antibodies against thyroid components." | 1.32 | [Hashimoto encephalopathy]. ( Günther, P; Kopf, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elger, CE | 1 |
| Rademacher, M | 1 |
| Brandt, C | 1 |
| Elmoufti, S | 1 |
| Dedeken, P | 1 |
| Eckhardt, K | 1 |
| Tennigkeit, F | 1 |
| De Backer, M | 1 |
| Günther, P | 1 |
| Kopf, A | 1 |
| Jabbari, B | 1 |
| Huott, AD | 1 |
| Yüksel, A | 1 |
| Yalçin, E | 1 |
| Cenani, A | 1 |
| O'Connor, RP | 1 |
| Persinger, MA | 1 |
| De Luca, F | 1 |
| Arrigo, T | 1 |
| Pandullo, E | 1 |
| Siracusano, MF | 1 |
| Benvenga, S | 1 |
| Trimarchi, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Le[NCT01375374] | Phase 3 | 11 participants (Actual) | Interventional | 2011-07-31 | Terminated (stopped due to Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading study center Investigators; decision thus made to terminate.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Due to premature termination of enrollment prior to achieving the planned sample size (a total of 28 subjects), this primary safety variable was assessed for descriptive purposes only. A negative value indicates an improvement. (NCT01375374)
Timeframe: From Day 1 (Baseline) to Day 84 (Treatment Period End)
| Intervention | nmol/L (Median) |
|---|---|
| Lacosamide | -12.80 |
The change in the serum thyroid hormone free thyroxine level from Baseline to the end of the Maintenance Period was summarized descriptively by visit. (NCT01375374)
Timeframe: From Day 1 (Baseline) to Day 84 (Treatment Period End)
| Intervention | pmol/L (Median) |
|---|---|
| Lacosamide | 2.70 |
The change in sex hormone calculated free androgen index (100 x Testosterone/sex hormone binding globulin) levels from Baseline to the end of Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement. (NCT01375374)
Timeframe: From Day 1 (Baseline) to Day 84 (Treatment Period End)
| Intervention | Free Androgen Index (Median) |
|---|---|
| Lacosamide | 9.493 |
The change in total cholesterol levels from Baseline to the end of the Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement. (NCT01375374)
Timeframe: From Day 1 (Baseline) to Day 84 (Treatment Period End)
| Intervention | mmol/L (Median) |
|---|---|
| Lacosamide | -0.540 |
2 trials available for thyroxine and Abdominal Epilepsy
| Article | Year |
|---|---|
Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial.
Topics: Acetamides; Adult; Anticonvulsants; Carbamazepine; Cholesterol; Dose-Response Relationship, Drug; Dr | 2016 |
Influence of long-term carbamazepine treatment on thyroid function.
Topics: Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Female; Humans; Male; Prospective Studi | 1993 |
4 other studies available for thyroxine and Abdominal Epilepsy
| Article | Year |
|---|---|
[Hashimoto encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Carbamazepine; Dementia, Vascular; Diagnosis, Differential; D | 2004 |
Seizures in thyrotoxicosis.
Topics: Adult; Aged; Epilepsies, Partial; Epilepsy; Female; Humans; Hyperthyroidism; Male; Middle Aged; Thyr | 1980 |
Increases in geomagnetic activity are associated with increases in thyroxine levels in a single patient: implications for melatonin levels.
Topics: Adult; Electromagnetic Fields; Epilepsies, Partial; Female; Humans; Hydrocortisone; Melatonin; Prola | 1996 |
Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxine-substituted hypothyroid children.
Topics: Carbamazepine; Child; Child, Preschool; Congenital Hypothyroidism; Epilepsies, Partial; Female; Huma | 1986 |